European drugmakers including AstraZeneca pony up for U.S.-listed biopharmas

European drugmakers announced a trio of deals around a billion dollars each to buy U.S.-listed biopharmas at hefty premiums
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.